A Phase 2, Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Long-Acting Lenacapavir in Combination With an Optimized Background Regimen in Treatment-experienced Adolescents and Children With HIV-1
Latest Information Update: 24 Jun 2025
At a glance
- Drugs Lenacapavir (Primary) ; Lenacapavir (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Gilead Sciences
Most Recent Events
- 18 Apr 2025 Planned End Date changed from 1 Aug 2026 to 1 Dec 2026.
- 18 Apr 2025 Planned primary completion date changed from 1 Mar 2026 to 1 Jun 2026.
- 18 Apr 2025 Status changed from not yet recruiting to recruiting.